HARP - Harpoon Therapeutics, Inc. Short-Term Debt to Capital

Symbol and logo of brand Harpoon Tx (HARP)

Harpoon Therapeutics (HARP) is a recognized leader in targeted tumor destruction utilizing the TriTAC system. The company's price evolution on the GURU.Markets platform is currently at 0.33. The business model relies on outsourcing clinical trials to external centers while maintaining full patent ownership. The firm's developments are based on creating high-precision antibodies that make malignant cells visible to the body's immune defense.

Current Liabilities to Capital: Harpoon Tx (HARP) for 07/04/2022 - 03/16/2024

Summary analytical data breakdowns for harpoontx.com (HARP)

- stock value and consensus price forecast:
Price Chart Harpoon Tx|HARP - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Harpoon Therapeutics Inc|HARP - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Harpoon Therapeutics|HARP - Total Stockholders' Equity|Market Value to Book Value Ratio harpoontx.com|HARP - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Harpoon Therapeutics|HARP - Long-Term Liabilities to Capital|Short-Term Debt to Capital Harpoon Therapeutics, Inc.|HARP - Company Total Indebtedness|Debt to Book Value Harpoon Therapeutics Inc|HARP - Long-Term Debt|Company Current Liabilities Harpoon Therapeutics|Quick Ratio harpoontx.com
- company profitability and valuation multiples indicators:
HARP - Net Financial Result
Initial company analysis:Harpoon Tx HARP
Signature product of harpoontx.com

The assessment of Harpoon Therapeutics (HARP) vulnerability to liquidity shocks is offset by its acquisition by a pharma behemoth, which shifts the risk of servicing obligations to the buyer. This chart of short-term liabilities as a percentage of capital measures the ratio of loans under one year to equity, allowing investors to determine the balance between the aggressive development of immunotherapy platforms and financial stability during the period of corporate integration.

Competitors of Harpoon Therapeutics (HARP)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|STRO: Short-Term Debt to Capital|INKT - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Werewolf Therapeutics Inc.|Short-Term Debt to Equity Ratio Immix (IMMX)|Short-Term Debt to Equity ALX Oncology (ALXO)|Short-Term Debt to Equity Ratio Cue Biopharma Inc. CUE|PDS Biotechnology Corporation - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Sonnet BioTherapeutics Holdings, Inc. SONN|MAIA - Short-Term Debt to Equity|LIMN (Liminatus) - Short-Term Debt to Capital Ratio|lavatherapeutics.com (LVTX) - Short-Term Debt to Equity|Current Liabilities to Capital nextcure.com (NXTC)|Short-Term Debt to Equity Ratio LPTX|INTS - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio SNSE (Sensei Biotherapeutics)|Short-Term Loans to Capital Ratio TOVX|Short-Term Debt to Capital GRTS (Gritstone bio)|Ratio of Short-Term Indebtedness to Capital KA|NexImmune - Short-Term Debt to Capital|Current Liabilities to Capital Turnstone Biologics|Vaccinex, Inc (VCNX) - Short-Term Debt to Equity